Silexion Therapeutics Set to Participate in Global Investment Conference
Silexion Therapeutics Corp. (“Silexion” or the “Company”) is gearing up to make a significant impact at the H.C. Wainwright 26th Annual Global Investment Conference. This event serves as a vital platform for showcasing cutting-edge technologies and building relationships within the investment community.
Conference Overview
The conference is scheduled to take place from September 9-11 at the prestigious Lotte New York Palace Hotel. This gathering of industry leaders and investors offers an outstanding opportunity for Silexion to present its innovative work in the oncology field.
Presentation Details
At the conference, Silexion's management will provide insightful presentations that detail the company's progress and future plans in cancer treatment. Attendees will be able to access a recorded version of this presentation on demand starting September 9, 2024, at 7:00 AM ET.
Opportunities for One-on-One Meetings
Investors looking to engage more closely will have the opportunity for one-on-one meetings with Silexion's management team. Those interested in scheduling a meeting are encouraged to reach out through their contact at H.C. Wainwright.
About Silexion Therapeutics
Silexion is not just another biotech company; it is at the forefront of combating solid tumor cancers linked to the mutated KRAS oncogene, which is recognized as a major contributor to various human cancers. The company’s commitment to innovation is highlighted by its Phase 2a clinical trial results, which show promising trends compared to traditional chemotherapy treatments.
Future Directions in Oncology
Silexion's primary focus remains on advancing its lead product candidate designed to treat locally advanced pancreatic cancer. Their relentless pursuit of innovation within oncology aims to provide substantial benefits to patients facing significant health challenges.
Contact Information
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investors
Chuck Padala
LifeSci Advisors
Chuck@lifesciadvisors.com
Frequently Asked Questions
What is Silexion Therapeutics known for?
Silexion Therapeutics is an innovative biotechnology company dedicated to developing treatments for solid tumor cancers associated with the mutated KRAS oncogene.
Where will the conference be held?
The H.C. Wainwright 26th Annual Global Investment Conference will be hosted at the Lotte New York Palace Hotel.
How can investors meet with Silexion's management?
Investors can schedule one-on-one meetings by contacting their representative at H.C. Wainwright.
When will the presentation be available?
The company presentation will be accessible on demand starting September 9, 2024, at 7:00 AM ET.
Who should be contacted for further information?
For additional inquiries, individuals can reach out to Mirit Horenshtein Hadar, the CFO of Silexion Therapeutics Corp, via email.